FibroBiologics (FBLG) announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts or other Tissue Factor-expressing cells to ...
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the ...
In a newly published review, Professor Xiao-Jun Huang's team at Peking University People's Hospital explore how haploidentical hematopoietic stem cell transplantation (haplo-HSCT), once limited by ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Every year, tens of thousands of people in the U.S. undergo ...
A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, can make the procedure ...
After an allogeneic stem cell transplant, a recipient’s body faces a daunting task: rebuilding the person’s blood-forming and immune systems from the ground up from a relatively small number of “seed” ...
Stem cell transplants remain essential for blood cancers, with expanded donor options including half-matched family members and umbilical cord blood. Cyclophosphamide has improved graft-versus-host ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback